
Pila Pharma Investor Relations Material
Latest events

Q4 2024
Pila Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Pila Pharma
Access all reports
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
PILA
Country
🇸🇪 Sweden